NewAmsterdam Pharma adds Adele Gulfo to its Board

NAARDEN, the Netherlands and MIAMI – NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a biopharmaceutical firm focused on developing oral treatments for cardiovascular disease (CVD), announced today the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo, a seasoned pharmaceutical executive with over 30 years of experience, is recognized for her global strategy and operations leadership, particularly in the commercialization of major medicines like LIPITOR® and CRESTOR®. The company, currently valued at $1.79 billion, maintains a strong financial position with more cash than debt on its balance sheet, according to InvestingPro data.

Michael Davidson, M.D., Ph.D., CEO of NewAmsterdam Pharma, expressed confidence in Gulfo’s ability to contribute to the company’s success, especially as they prepare for the potential launch of their new drug candidate, obicetrapib, in the upcoming year. Gulfo’s prior roles include Chief Executive Officer at Sumitomo Pharma America, as well as key positions at Sumitovant Biopharma, Roivant Sciences, Pfizer, and AstraZeneca. Her commercial acumen and track record of launching successful therapies are expected to be valuable assets to NewAmsterdam Pharma. The company’s robust financial health is reflected in its impressive current ratio of 8.08, indicating strong ability to meet short-term obligations. For deeper insights into NAMS’s financial health and growth potential, investors can access comprehensive analysis through InvestingPro’s detailed research reports.

Gulfo, who also serves on the boards of other public companies and is involved with the Innovation Growth Board at Mass General Brigham, expressed enthusiasm about joining NewAmsterdam’s Board during a transformative period for the company. She cited the firm’s progress, including positive outcomes from three pivotal Phase 3 clinical trials, as indicative of its potential to improve treatment for CVD patients.

NewAmsterdam Pharma is investigating obicetrapib, a once-daily oral CETP inhibitor, intended to be used alongside statin therapy for CVD patients with elevated LDL-C levels who have not had success with existing treatments. The company’s mission is to address the unmet need for safe, well-tolerated, and convenient LDL-C lowering therapies.

This news is based on a press release statement and includes forward-looking statements regarding NewAmsterdam’s strategic plans and potential product launches. These statements are not guarantees of future performance and are subject to risks and uncertainties, including regulatory approvals and market conditions. Recent market data from InvestingPro shows the stock has gained 7.58% over the past week, though analysts do not anticipate profitability this year. The company’s stock is currently trading below its InvestingPro Fair Value, suggesting potential upside opportunity for investors.

In other recent news, NewAmsterdam Pharma Co NV has seen a notable adjustment in its financial outlook. Scotiabank analyst George Farmer raised the price target for NewAmsterdam Pharma shares to $52, up from $47, while maintaining a Sector Outperform rating. This change reflects anticipated positive developments from upcoming medical meetings and publications expected to highlight the effectiveness of the company’s CETP inhibitor, obicetrapib. The analyst points to strong data from three Phase 3 trials that demonstrated obicetrapib’s ability to significantly lower LDL-C, or bad cholesterol, as a key factor in this outlook. NewAmsterdam Pharma’s financial stability is reinforced by a cash position of $834 million, sufficient to support operations through the commercialization phase. Additionally, the company is preparing for regulatory filings in the U.S. and EU in the second half of 2025. Scotiabank suggests that NewAmsterdam Pharma is well-positioned for a potential acquisition, which could aid in the commercialization of obicetrapib. The revised price target also considers the extension of intellectual property protection to 2043, enhancing the drug’s market exclusivity prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.